XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Changes in Fair Value of Derivative Liabilities

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of March 31, 2020:

 

    Conversion Feature  
Balance at December 31, 2019   $ 540,517  
New derivative liability     870,268  
Reclassification to additional paid in capital from  conversion of debt to common stock     (368,811 )
Change in fair value     736,298  
         
Balance at March 31, 2020   $ 1,778,272  
Summary of Estimate Fair Value of Derivative Liabilities

The Company used the following assumptions to estimate fair value of the derivatives as of March 31, 2020:

 

    March 31, 2020  
    Key Assumptions for  
    fair value of conversions  
Risk free interest     0.23% to 2.26 %
Market price of share   $ 0.17  
Life of instrument in years     2.06 - 2.35  
Volatility     150.65 %
Dividend yield     0 %
Schedule of Fair Value Measurements

Below is the fair value measurements for the investments in equity securities that the Company held as of March 31, 2019:

 

As of March 31, 2019   Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
Investments in Equity Securities                                        
Adhera Therapeutics – Convertible Series E Preferred Shares   $ -     $ -     $ -     $ 1,769,300     $ 1,769,300  
    $ -     $ -     $ -     $ 1,769,300     $ 1,769,300  
Schedule of Changes in Fair Value Measurements

The change in the value of the investment, under level 3 of the Fair Value Measurement, is shown as under:

 

    Year Ended  
    December 31, 2019  
       
Opening Balance   $ 1,769,300  
Value introduced     -  
Write off value of investment     (1,769,300 )
Closing balance   $ -  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive:

 

    Three Months Ended March 31,  
    2020     2019  
             
Convertible notes     12,084,300       -  
Stock options     6,135,284       -  
Warrants     15,237,500       -  
Potentially dilutive securities     33,457,084       -